APAC CAR T cell Therapy Market

APAC CAR T cell Therapy Market Size (2023 to 2028)

The CAR T cell Therapy Market size in the Asia Pacific is estimated to grow at a robust CAGR from 2023 to 2028.

Increased funds from the government organizations and the adoption of advanced technologies in the hospitals and clinics are undoubtedly significant factors for the market to grow in the Asia Pacific. It is proven that CAR T cell therapy is very much efficient in treating cancer, and this is elevating the growth rate of the market enormously. Growing older people is one more factor propelling the CAR T cell therapy market's demand in the Asia Pacific. An increasing number of people suffering from chronic diseases is accelerating the size of the market. In the Asia Pacific, more than 2000 clinical trials were going on with this technique, which is solely enhancing the market demand. 

However, this treatment procedure's cost is very high, where ordinary people cannot afford is slowly impeding the growth rate of the CAR T cell therapy market in the Asia Pacific. Stringent rules and regulations by the government in approving new techniques are limiting the demand of the market. Besides, the shortage of skilled professionals in the laboratories to perform clinical trials is hampering the market's demand. Inadequate reimbursement policies in underdeveloped countries are likely to show a negative impact on the growth rate of the market. 

This research report on the Asia Pacific CAR T cell therapy market has been segmented and sub-segmented into the following categories:

By Target Antigen

• CD20
• EGFRV III
• CD19
• HER2
• MESO
• CD22
• BCMA
• GD2
• CD30
• HER1
• CD33

By Application

• Multiple Myeloma
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Follicular Lymphoma
• Diffuse large B-cell lymphoma
• Acute Lymphoblastic Leukemia

By Product

• Allogeneic
• Autologous

By Therapies:

• Axicabtagene ciloleucel (Yescarta)
• Tisagenlecleucel (Kymriah)

By End-User

• Cancer Research Centers
• Hospitals
• Academic and Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations

Country-Level Analysis:

Asia Pacific is estimated to reach the highest CAGR in the coming years. Growing knowledge over the availability of different treatment procedures through digital advertisements bolsters the CAR T cell therapy market's growth. 

China is leading with the highest shares of the market by owing to the increasing number of hospitals with excellent infrastructure. The launch of innovative techniques with advanced technologies is surging the demand of the market. According to the recent survey, around 4.3 million people have cancer in China. 

India is next to China in dominating the shares of the CAR T cell therapy market. The number of cancer cases in India is projected to surge in the coming years due to lifestyle changes. Increasing pharmaceutical companies and a rise in the number of clinical trials are fuelling the market's growth rate. The introduction of these techniques to treat cancer is elevating this market's demand for this country's extent.

Japan is esteemed to have significant growth opportunities in the coming years with the growing economy from the past few years. Also, focusing on improving the quality of healthcare services by introducing various techniques is boosting market demand.  

Notable companies in the APAC CAR T Cell Therapy Market profiled in this report are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc. and Pfizer, Inc.